Table 3.
Multivariate analysis for relapse-free survival of patients
| Variable | Hazard ratio | 95% CI | p-value |
|---|---|---|---|
| Age (< 50 yr vs. > 50 yr) | 0.77 | 0.53-1.11 | 0.157 |
| Histologic grade 1 | 1 | 0.001 | |
| Histologic grade 2 | 1.2 | 0.37-3.92 | |
| Histologic grade 3 | 2.59 | 0.78-8.57 | |
| Histologic grade NA | 1.27 | 0.33-4.94 | |
| Subtype: HR+/HER2- | 1 | < 0.001 | |
| Subtype: HER2+ | 1.69 | 1.02-2.79 | |
| Subtype: TNBC | 4.97 | 3.24-7.61 | |
| pCR (ypT0/isN0) vs. non-pCR | 0.26 | 0.08-0.86 | 0.027 |
| ypT stage 0 | 1 | < 0.001 | |
| ypT stage 1 | 0.85 | 0.39-1.83 | |
| ypT stage 2 | 1.96 | 0.90-4.24 | |
| ypT stage 3 | 1.95 | 0.69-3.95 | |
| ypT stage 4 | 5.93 | 1.63-21.58 | |
| ypN stage 0 | 1 | 0.035 | |
| ypN stage 1 | 1.72 | 1.04-2.84 | |
| ypN stage 2 | 2.69 | 1.27-5.71 | |
| ypN stage 3 | 3.39 | 1.43-8.01 | |
| Lymphovascular invasion (yes vs. no) | 1.5 | 1.02-2.22 | 0.040 |
| LNR low (0-0.20) | 1 | 0.954 | |
| LNR intermediate (0.21-0.65) | 1.01 | 0.55-1.86 | |
| LNR high (0.66-1.00) | 1.12 | 0.48-2.59 |
CI, confidence interval; NA, not available; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; pCR, pathologic complete response; LNR, lymph node ratio.